Myeloma as a model for the process of metastasis: implications for therapy.
暂无分享,去创建一个
[1] D. Chauhan,et al. Targeting signalling pathways for the treatment of multiple myeloma , 2005, Expert opinion on therapeutic targets.
[2] S. Colla,et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. , 2004, Blood.
[3] A. Zannettino,et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma , 2011, Leukemia.
[4] R. Hayes,et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.
[5] Robert A. Weinberg,et al. Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.
[6] C. Melief,et al. B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.
[7] D. Scadden. Circadian rhythms: Stem cells traffic in time , 2008, Nature.
[8] David W. Rowe,et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche , 2009, Nature.
[9] F. Gervasi,et al. Targeting Multiple Myeloma Cells and Their Bone Marrow Microenvironment , 2004, Annals of the New York Academy of Sciences.
[10] O. Sezer. Myeloma bone disease , 2005, Hematology.
[11] P. Richardson,et al. The malignant clone and the bone-marrow environment. , 2007, Best practice & research. Clinical haematology.
[12] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[13] M. Dimopoulos,et al. Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis , 2005, Leukemia & lymphoma.
[14] Takahiro Ochiya,et al. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.
[15] R. Alon,et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. , 2000, Blood.
[16] Charles P. Lin,et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. , 2009, Blood.
[17] B. Barlogie,et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity , 2002, British journal of haematology.
[18] R. Taichman,et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4 , 2002, Nature Immunology.
[19] A. Régnault,et al. TCR Activation of Human T Cells Induces the Production of Exosomes Bearing the TCR/CD3/ζ Complex1 , 2002, The Journal of Immunology.
[20] Robert A Kyle,et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. , 2005, Blood.
[21] R. Weinberg,et al. miR-31: A crucial overseer of tumor metastasis and other emerging roles , 2010, Cell cycle.
[22] R. Carrasco,et al. Pathogenesis of myeloma. , 2011, Annual review of pathology.
[23] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[24] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[25] G. Downey,et al. L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration. , 2003, Blood.
[26] L. Young,et al. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model , 2005, Leukemia.
[27] M. Korpal,et al. The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.
[28] Charles P. Lin,et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. , 2012, Blood.
[29] Ulrich H. von Andrian,et al. Stem Cell Trafficking in Tissue Development, Growth, and Disease , 2008, Cell.
[30] S. Rafii,et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis , 2004, Nature Medicine.
[31] H. Döhner,et al. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.
[32] Y. Tai,et al. Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma , 2011 .
[33] P. Croucher,et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.
[34] Bart Barlogie,et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. , 2007, Blood.
[35] Charles P. Lin,et al. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. , 2011, Journal of biomedical optics.
[36] R. Alon,et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. , 2000, Blood.
[37] R. Kyle,et al. Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 Years , 1996, British journal of haematology.
[38] E. Ocio,et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. , 2011, Blood.
[39] A. Hidalgo,et al. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.
[40] N. Mechti,et al. IL-6 regulates CD44 cell surface expression on human myeloma cells , 2004, Leukemia.
[41] N. Halama,et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications , 2011, British journal of haematology.
[42] C. Hart,et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. , 2010, Blood.
[43] S. Rajkumar. ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES: A CONTINUING MEDICAL EDUCATION SERIES Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management , 2010 .
[44] R. Alon,et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. , 1999, The Journal of clinical investigation.
[45] Hong Chang,et al. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. , 2009, Leukemia research.
[46] Xin Lu,et al. Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis , 2010, Clinical Cancer Research.
[47] T. Martin,et al. The Osteoblast-specific Transcription Factor Cbfa1 Contributes to the Expression of Osteoprotegerin, a Potent Inhibitor of Osteoclast Differentiation and Function* , 2000, The Journal of Biological Chemistry.
[48] Robert A. Weinberg,et al. A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .
[49] Andrés Hidalgo,et al. Integrin α4β1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion , 2004 .
[50] S. Ergün,et al. Endothelial and Hematopoietic Progenitor Cells (EPCs and HPCs): Hand in Hand Fate Determining Partners for Cancer Cells , 2008, Stem Cell Reviews.
[51] B. Barlogie,et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.
[52] N. Munshi,et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. , 2009, Cancer cell.
[53] T. Komori. Regulation of skeletal development by the Runx family of transcription factors , 2005, Journal of cellular biochemistry.
[54] A. Órfão,et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. , 1999, Blood.
[55] D. Chauhan,et al. Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.
[56] P. Selby,et al. Proteomic analysis of melanoma‐derived exosomes by two‐dimensional polyacrylamide gel electrophoresis and mass spectrometry , 2004, Proteomics.
[57] Hong Zhang,et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. , 2005, Blood.
[58] T. Lapidot. Mechanism of Human Stem Cell Migration and Repopulation of NOD/SCID and B2mnull NOD/SCID Mice , 2001, Annals of the New York Academy of Sciences.
[59] G. Morgan,et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial , 2011, The Lancet. Oncology.
[60] G. Stein,et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. , 2008, The Journal of clinical investigation.
[61] S. Ramaswamy,et al. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.
[62] R. Weinberg,et al. MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis , 2009, Cell cycle.
[63] R. Kyle,et al. IgD monoclonal gammopathy with long‐term follow‐up , 1994, British journal of haematology.
[64] W. Dalton,et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. , 1999, Blood.
[65] I. Fidler,et al. AACR centennial series: the biology of cancer metastasis: historical perspective. , 2010, Cancer research.
[66] G. Mundy,et al. A murine model of myeloma that allows genetic manipulation of the host microenvironment , 2009, Disease Models & Mechanisms.
[67] D. Peeper,et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB , 2004, Nature.
[68] N. Clarke,et al. Parathyroid hormone-related peptide: expression in prostate cancer bone metastases , 2002, Prostate Cancer and Prostatic Diseases.
[69] D. Scadden,et al. Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.
[70] M. Washington,et al. TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.
[71] D. Hedley,et al. Cancer stem cells, hypoxia and metastasis. , 2009, Seminars in radiation oncology.
[72] Charles P. Lin,et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. , 2007, Blood.
[73] W. Dupont,et al. Markers of Epithelial-Mesenchymal Transition and Epithelial Differentiation in Sarcomatoid Carcinoma: Utility in the Differential Diagnosis With Sarcoma , 2008, Applied immunohistochemistry & molecular morphology : AIMM.
[74] K. Podar,et al. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. , 2010, Cell cycle.
[75] H. Döhner,et al. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.
[76] Xunbin Wei,et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.
[77] R. Fonseca,et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. , 2003, Blood.
[78] C. Théry,et al. Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.
[79] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[80] Makoto Sato,et al. Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.
[81] A. Devys,et al. [PTHrP and breast cancer]. , 2001, Bulletin du cancer.
[82] I. Fidler. The biology of cancer metastasis. , 2011, Seminars in cancer biology.
[83] J. Chirgwin,et al. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.
[84] G. Morgan,et al. Novel drugs in myeloma: harnessing tumour biology to treat myeloma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[85] R. Schofield. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. , 1978, Blood cells.
[86] N. Altorki,et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. , 2009, Biochimica et biophysica acta.
[87] M. Ratajczak,et al. Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis , 2005, Stem cells.
[88] Andrés Hidalgo,et al. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. , 2004, Experimental cell research.
[89] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[90] E. Lander,et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.
[91] J. Churg,et al. Multiple myeloma; lesions of the extra-osseous hematopoietic system. , 1950, American journal of clinical pathology.
[92] D. Scadden,et al. Stem-cell ecology and stem cells in motion. , 2008, Blood.
[93] Linheng Li,et al. The stem cell niches in bone. , 2006, The Journal of clinical investigation.
[94] C. Mitsiades. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.
[95] Laurence Zitvogel,et al. Molecular Characterization of Dendritic Cell-Derived Exosomes , 1999, The Journal of cell biology.
[96] Kou-Juey Wu,et al. TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development , 2008, Cell cycle.
[97] Simon C Watkins,et al. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[98] Charles P. Lin,et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.
[99] K. Anderson,et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. , 2003, Cancer research.
[100] M. Olivotto,et al. The role of hypoxia in the maintenance of hematopoietic stem cells. , 1993, Blood.
[101] S. Orkin,et al. Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow Microenvironment , 2007, Cell.
[102] M. Audran,et al. PTHrP et cancer du sein , 2001 .
[103] William E. Grizzle,et al. Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1 , 2006, The Journal of Immunology.
[104] K. Vanderkerken,et al. The role of the bone marrow microenvironment in multiple myeloma. , 2005, Histology and histopathology.
[105] G. Roodman. Mechanisms of bone metastasis. , 2004, Discovery medicine.
[106] D. Ribatti,et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells , 2010, Leukemia.
[107] W. Dalton,et al. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR) , 2000, Oncogene.
[108] R. Kyle,et al. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma , 2010, Current hematologic malignancy reports.
[109] R. Sanderson,et al. Heparanase Regulates Levels of Syndecan-1 in the Nucleus , 2009, PloS one.
[110] C. Cordon-Cardo,et al. A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.
[111] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[112] P. Tassone,et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. , 2011, Blood.
[113] J. Body,et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[114] D. Scadden,et al. The stem-cell niche as an entity of action , 2006, Nature.
[115] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] F. Su,et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells , 2011, Molecular Cancer.
[117] A. Nagler,et al. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. , 2003, The Journal of clinical investigation.
[118] F. Prósper,et al. Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment , 2010 .
[119] M. Ratajczak,et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. , 2005, Blood.
[120] D. Piwnica-Worms,et al. CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.
[121] H. Lokhorst,et al. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma , 2012, Leukemia.
[122] F. Saad. Src as a therapeutic target in men with prostate cancer and bone metastases , 2009, BJU international.
[123] J. Bladé,et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] M. Mason,et al. Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.
[125] I. Macdonald,et al. Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.
[126] Terry M Therneau,et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.
[127] Y. Matsuki,et al. Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.
[128] Bethan Psaila,et al. The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.
[129] Cameron P Bracken,et al. MicroRNAs as regulators of epithelial-mesenchymal transition , 2008, Cell cycle.
[130] B. Pan,et al. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor , 1983, Cell.
[131] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[132] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[133] K. Anderson,et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.
[134] G. Raposo,et al. Exosomes: a common pathway for a specialized function. , 2006, Journal of biochemistry.
[135] Y. Khotskaya,et al. Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumors in Vivo* , 2009, The Journal of Biological Chemistry.
[136] G. Raposo,et al. Intestinal epithelial cells secrete exosome-like vesicles. , 2001, Gastroenterology.
[137] R. Kaplan,et al. Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. , 2006, Breast disease.
[138] F. Sim,et al. Solitary plasmacytoma of bone: Mayo Clinic experience. , 1989, International journal of radiation oncology, biology, physics.
[139] Veronica Huber,et al. Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles , 2002, The Journal of experimental medicine.
[140] P. Richardson,et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. , 2001, Seminars in oncology.
[141] P. Giri,et al. Exosomes Derived from M. Bovis BCG Infected Macrophages Activate Antigen-Specific CD4+ and CD8+ T Cells In Vitro and In Vivo , 2008, PloS one.
[142] J. Rak. Microparticles in cancer. , 2010, Seminars in thrombosis and hemostasis.
[143] R. Fonseca,et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] Konstantinos Konstantopoulos,et al. Cancer cells in transit: the vascular interactions of tumor cells. , 2009, Annual review of biomedical engineering.
[145] K. Pienta,et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. , 2011, The Journal of clinical investigation.
[146] R. Weinberg,et al. Chemokine networks and breast cancer metastasis. , 2006, Breast disease.
[147] Charles P. Lin,et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. , 2011, Blood.
[148] K. Anderson,et al. Characterization of adhesion molecules on human myeloma cell lines. , 1992, Blood.
[149] Paula D. Bos,et al. Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.
[150] R. Weinberg,et al. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.
[151] T. Flores,et al. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma , 2010, European journal of haematology.
[152] G. Raposo,et al. Accumulation of Major Histocompatibility Complex Class Ii Molecules in Mast Cell Secretory Granules and Their Release upon Degranulation Generation of Bmmcs Preparation of B Cells Reagents and Monoclonal Antibodies (mabs) Immunofluorescence Staining and Confocal Microscopy Pulse-chase# Labeling and , 2022 .
[153] Charles P. Lin,et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. , 2009, Blood.